Assessment of metabolic profile in a clinical setting

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 9, Issue 5, 2006, Pages 589-595

  Pervanidou, Panagiota ^a,b   Kanaka Gantenbein, Christina ^a   Chrousos, George P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Cardiovascular disease; Dyslipidemia; Hypertension; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; LIVER ENZYME; SERUM AMYLOID A; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 1; URIC ACID;

ATHEROSCLEROSIS; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FAMILY HISTORY; FATTY LIVER; GENE MUTATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FUNCTION; LABORATORY TEST; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OVARY POLYCYSTIC DISEASE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PROTEINURIA; REVIEW; ULTRASOUND; URIC ACID BLOOD LEVEL; WAIST HIP RATIO; WORLD HEALTH ORGANIZATION;

ADIPOSE TISSUE; BODY COMPOSITION; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; RISK ASSESSMENT; RISK FACTORS; WAIST-HIP RATIO;

EID: 33747453088     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000241669.24923.8d     Document Type: Review

References (53)

1. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
2. Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med 2006; 119 (Supp1):S3-S9. •A very good review on metabolic syndrome and type 2 diabetes, covering many aspects.
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
4. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366:1059-1062. •The current IDF definition of the metabolic syndrome. The fact that waist circumference is considered as a fixed component of the definition of metabolic syndrome points to the impact of central obesity on CVD risk.
5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
6. Weiss R, Dziura J, Burgert TS, et al. Obesity and metabolic syndrome in children and adolescents. N Engl J Med 2004; 350:2362-2374.
7. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28:1769-1778. •Very good review on mortality and CVD risks.
8. Invitti C, Maffeis C, Gilardini L, et al. Metabolic syndrome in obese Caucasian children: prevalence using WHO-derived criteria and association with nontraditional cardiovascular risk factors. Int J Obes 2006; 30:627-633. •Important study for the pediatric population.
9. Ramadhani MK, Grobbee DE, Bots ML, et al. Lower birth weight predicts metabolic syndrome in young adults: the Atherosclerosis Risk in Young Adults (ARYA)-study. Atherosclerosis 2006; 184:21-27. •The hot issue of fetal origins of adult disease is again discussed.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
11. Flegal KM, Caroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723-1727.
12. Lorenzo C, Williams K, Hunt KJ, Haffner S. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care 2006; 29:625-630. •A large study on the prevalence of metabolic syndrome.
13. Sharma AM, Chetty VT. Obesity, hypertension and insulin resistance. Acta Diabetol 2005; 42:S3-S8.
14. Speiser PW, Rudolf MCJ, Anhalt H, et al., on behalf of the Obesity Consensus Working Group. Consensus statement: childhood obesity. J Clin Endocrinol Metab 2005; 90:1871-1887. ••An important consensus statement on obesity in this critical age; definitions in this area are not very well clarified.
15. Racette SB, Evans EM, Weiss EP, et al. Abdominal adiposity is a stronger predictor of insulin resistance than fitness among 50-95 year olds. Diabetes Care 2006; 29:673-678. •This paper supports the measurement of waist circumference as a marker of central obesity and as a strong predictor for CVDs in older adults.
16. Ktzmarzyk PT, Janssen I, Poss R, et al. The importance of waist circumference in the definition of metabolic syndrome. Diabetes Care 2006; 29: 404-409. ••This paper discusses the relevance of waist circumference to metabolic risk.
17. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102:179-184.
18. Patel A, Huang KC, Janus ED, et al. Is a single definition of the metabolic syndrome appropriate? A comparative study of the USA and Asia. Atherosclerosis 2006; 184:225-232. ••Studies in different populations make clear that the metabolic syndrome cannot have a unified definition.
19. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
20. Su Ta-Chen, Jeng JS, Chien KL, et al. Hypertension status is the major determinant of carotid atherosclerosis: a community-based study in Taiwan. Stroke 2001;32:2265-2271.
21. Puig JG, Ruilope LM, Luque M, et al., AVANT Study Group Investigators. Metabolism in patients with essential hypertension. Am J Med 2006; 119:318-326.
22. Su TC, Lee YT, Chou S, et al. Twenty-four hour ambulatory blood pressure and duration of hypertension as major determinants for intima-media thickness and atherosclerosis of carotid arteries. Atherosclerosis 2006; 184: 151-156. •Twenty-four-hour blood pressure is a better predictor of CVD than the single office blood pressure measurement.
23. Nigro J, Osman N, Dart AM, Little PJ. Insulin resistance and atherosclerosis. Endocr Rev 2006; May 27(3):242-259 [Epub ahead of print]. ••This very good review article explains the pathophysiology of the link between insulin resistance and atherosclerosis.
24. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289-2304.
25. Johnson JS, Johnson BD, Allison TG, et al. Correspondence between the Adult Treatment Panel III criteria for metabolic syndrome and insulin resistance. Diabetes Care 2006; 29:668-672. •This study assesses the diagnostic accuracy of the ATPIII definition of the metabolic syndrome in identifying insulin resistance.
26. Saely CH, Aczel S, Marte T, et al. The metabolic syndrome, insulin resistance and cardiovascular risk in diabetic and nondiabetic patients. J Clin Enocrinol Metab 2005; 90:5698-5703. •This study elucidates the role of insulin resistance as a risk factor beyond diabetes.
27. Wiegand S, Dannemann A, Krude H, Gruters A. Impaired glucose tolerance and type 2 diabetes mellitus: a new field for pediatrics in Europe. Int J Obes (Lond) 2005; 29 (Suppl 2):S136-S142.
28. Muntner P, He J, Chen J, et al. Prevalence of nontraditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004; 14:686-695.
29. Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein (a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005; 51:2067-2073. •This paper clarifies the role of Lp(a) as a predictive factor for CVD in heterozygous patients with familial hypercholesterolemia, which is very common in the general population.
30. Erhardt LR, Gotto A Jr. The evolution of European guidelines: changing the management of cholesterol levels. Atherosclerosis 2006; 185: 12-20. ••Important paper on cholesterol management.
31. Pang RWC, Tam S, Janus ED, et al. Plasma lipid, lipoprotein and apolipoprotein levels in a random population sample of 2875 Hong Kong Chinese adults and their implications (NCEP ATP-III, 2001 guidelines) on cardiovascular risk assessment. Atherosclerosis 2006; 184: 438-445.
32. Okamura T, Hayakawa T, Kadowaki T, et al., The NIPPON DATA90 Research Group. The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis 2006; 184: 143-150. •This study suggests the important role of HDL cholesterol in assessing CVD risk in an Asian population.
33. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol 2006; 64:355-365.
34. Mohan V, Deepa R, Pradeepa R, et al. Association of low adiponectin levels with the metabolic syndrome: the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 2005; 54:476-481.
35. Thorand B, Baumert J, Doring A, et al., for the KORA Group. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006; 184:216-224. •This study suggests that sexual dimorphism affects subclinical inflammation status in obese individuals.
36. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
37. Nassis GP, Papantakou K, Skenderi K, et al. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin and inflammatory markers in overweight and obese girls. Metabolism 2005; 54:1472-1479.
38. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 (Suppl 1):S5-S10.
39. Rocha R, Cotrim HP, Carvalho FM, et al. Body mass index and waist circumference in nonalcoholic fatty liver disease. J Hum Nutr Diet 2005; 18:365-370.
40. Schlachter M. Uric acid and hypertension. Curr Pharm Des 2005; 11:4139-4143.
41. Dell'Omo G, Penno G, Giorgi D, et al. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis 2002; 40:1-8.
42. Luque M, de Rivas B, Alvarez B, et al. Influence of target organ lesion detection (assessment of microalbuminuria and echocardiogram) in cardiovascular risk stratification and treatment of untreated hypertensive patients. J Hum Hypertens 2006; 20:187-192.
43. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249:519-526.
44. Ritz E. Heart and kidney: fatal twins? Am J Med 2006; 119 (5 suppl 1): S31-S39.
45. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110:32-35.
46. Rosmond R. Association studies of genetic polymorphisms in central obesity: a critical review. Int J Obes 2003; 27:1141-1151.
47. Kalme T, Seppala M, Riitta QQ, et al. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 2005; 90:1550-1556.
48. Kupelian V, Page S, Araujo AB, et al. Low sex hormone-binding globulin, total testosterone and symptomatic androgen deficiency are associated with development of the metabolic syndrome in non-obese men. J Clin Endocrinol Metab 2006; 91:843-850.
49. Azziz R. The Rotterdam 2003 criteria for defining PCOS: CON. J Clin Endocrinol Metab 2006; 91:781-785.
50. Ehrman DA, Liljenquist DR, Kasza K, et al., for the PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48-53. •Very important paper showing the relation between PCOS and the metabolic syndrome.
51. Carmina E, Chu MC, Longo A, et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005; 90:2545-2549. •This study shows that the prevalence of CVD risk differs among phenotypes in women with hyperandrogenism.
52. Zanolin ME, Tosi F, Zoppini G, et al. Clustering of cardiovascular risk factors associated with the insulin resistance syndrome: assessment by principal component analysis in young hyperandrogenic women. Diabetes Care 2006; 29:372-378. •An important paper defining the necessity of metabolic risk assessment in the PCOS group.
53. Dos Santos RE, Aldrighi JM, Lanz JR, et al. Relationship of body fat distribution by waist circumference, dual-energy X-ray absorptiometry and ultrasonography to insulin resistance by homeostasis model assessment and lipid profile in obese and nonobese postmenopausal women. Gynecol Endocrinol 2005; 21:295-301.